While we have identified promising potential modifier variants in NFU1, DMD, HPS5, CLDN8 and CLDN17, their functional impact on FHHNC progression towards kidney failure remains to be characterized. This evidence concerns the gene CLDN17 and familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis.